Akoya Biosciences, NeraCare Partner to Develop Melanoma Tests
Source: Genome Web, May 2024
NEW YORK – Spatial biology company Akoya Biosciences and German prognostic test developer NeraCare said Thursday that they have inked an exclusive agreement to develop assays for skin cancer.
Financial terms of the deal were not disclosed.
As part of the collaboration, the companies will codevelop tests that combine Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification and therapy selection in early-stage melanoma patients.